University of Tennessee West Cancer Center | Strategic Alliance Partners

West Cancer Center & Research Institute is the leader in comprehensive adult cancer care led by providers to provide the most positive outcomes though research, novel therapies, advanced treatments, and cancer prevention to all patients, regardless of socioeconomic status. With over 40 years of oncology expertise, 100+ specialists, 8 locations and over 47,000 patients in 2021- West is positioned as the first choice for cancer care in the Mid-South and a national model for comprehensive care.

Connect with us:

Latest from University of Tennessee West Cancer Center

Dr. Grothey on the DESTINY-CRC01 Trial With Trastuzumab Deruxtecan in HER2+ CRC

December 22, 2020

Video

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16, 2020

Video

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11, 2020

Video

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22, 2020

Video

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

September 15, 2020

Video

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC

September 14, 2020

Video

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 02, 2020

Video

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Later-Line Treatment Approaches Make Headway in CRC Management

September 02, 2020

Article

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Dr. VanderWalde on Utility of Radiation Therapy in Rectal Cancer

September 01, 2020

Video

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31, 2020

Video

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm

August 26, 2020

Video

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Rapid Progress in HCC Paradigm Shifts Standards, Sequencing Strategies

August 20, 2020

Article

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Rectal Cancer Treatment Enters an Era of Personalized Medicine

August 19, 2020

Article

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Dr. VanderWalde on Future Research in Rectal Cancer

August 13, 2020

Video

Noam VanderWalde, MD, MS, discusses where future research efforts should focus in rectal cancer.

Dr. Somer on the Clinical Implications of Atezolizumab/Bevacizumab Approval in HCC

August 13, 2020

Video

Bradley G. Somer, MD, discusses the clinical implications of the FDA approval of atezolizumab in combination with bevacizumab in unresectable or metastatic hepatocellular carcinoma.

Schwartzberg Sheds Light on Rise of Biosimilars in Oncology

February 06, 2020

Article

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

January 17, 2020

Video

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 04, 2020

Video

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

December 04, 2019

Video

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

West Cancer Center Faculty Walk Through Ongoing Breast Cancer Research Efforts

November 27, 2019

Article

Experts from West Cancer Center highlighted the exciting research being conducted at their institution.